Mammalian target of rapamycin as a target in hematological malignancies

被引：15
|
作者：
Kelly, Kevin R. [1 ]
Rowe, Julie H. [1 ]
Padmanabhan, Swaminathan [1 ]
Nawrocki, Steffan T. [1 ]
Carew, Jennifer S. [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
TARGETED ONCOLOGY | 2011年 / 6卷 / 01期
关键词：
mTOR; Hematological malignancies; Novel agents; Targeted therapy; ACUTE MYELOID-LEUKEMIA; MANTLE CELL LYMPHOMA; SINGLE-AGENT TEMSIROLIMUS; PHASE-II TRIAL; EVERY; WEEKS; MULTIPLE-MYELOMA; IN-VIVO; INHIBITOR EVEROLIMUS; PHOSPHOINOSITIDE; 3-KINASE; DEFOROLIMUS AP23573;
D O I：
10.1007/s11523-011-0175-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.
引用
收藏
页码：53 / 61
页数：9
相关论文
共 50 条
  • [31] The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma
    Gera, Joseph
    Lichtenstein, Alan
    LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1857 - 1866
  • [32] Mammalian Target of Rapamycin as a Novel Target in the Treatment of Hepatocellular Carcinoma
    Guo, Yu
    Liang, Xinjun
    Lu, Minqiang
    Weng, Taohua
    Liu, Yanyan
    Ye, Xiaoming
    HEPATO-GASTROENTEROLOGY, 2010, 57 (101) : 913 - 918
  • [33] Analysis of ovarian mammalian target of rapamycin (mTOR) signalling components in borderline gynaecological malignancies
    Rai-Rogers, Karly
    Goumenou, Anastasia
    Pados, George
    Karteris, Emmanouil
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 30 : S65 - S65
  • [34] Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies
    Witzig T.E.
    Kaufmann S.H.
    Current Treatment Options in Oncology, 2006, 7 (4) : 285 - 294
  • [35] Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
    Teachey, David T.
    Grupp, Stephan A.
    Brown, Valerie I.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (05) : 569 - 580
  • [36] Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells
    Edinger, AL
    Linardic, CM
    Chiang, GG
    Thompson, CB
    Abraham, RT
    CANCER RESEARCH, 2003, 63 (23) : 8451 - 8460
  • [37] Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
    Da-zhi Xu
    Qi-rong Geng
    Ying Tian
    Mu-yan Cai
    Xin-juan Fang
    You-qing Zhan
    Zhi-wei Zhou
    Wei Li
    Ying-bo Chen
    Xiao-wei Sun
    Yuan-xiang Guan
    Yuan-fang Li
    Tong-yu Lin
    BMC Cancer, 10
  • [38] Mammalian target of rapamycin (mTOR) as a target for cancer therapeutic development.
    Dancey, J
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3823S - 3824S
  • [39] Mammalian target of rapamycin: Biological function and target for novel anticancer agents
    Borders, Emily B.
    Bivona, Cory
    Medina, Patrick J.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (24) : 2095 - 2106
  • [40] Mammalian target of rapamycin ( mTOR) as a potential therapeutic target in various diseases
    Kaur, Avileen
    Sharma, Saurabh
    INFLAMMOPHARMACOLOGY, 2017, 25 (03) : 293 - 312
12345